Cybin D/B/A Helus Pharma HELP
9.19 USD +0.38 (+4.37%)
Nov 3, 2026, 3:21 PM EST
8.94 Day range 9.57
3.76 52-week range 15.15
- YTD
- +12.29%
- 1 year
- +36.48%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 40.24 +338.1% upside
Now 9.19
- Target (low)
- 15.08
- Target (mean)
- 40.24
- Target (high)
- 69.16
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy1
- Buy10
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 10
- 2 months ago 10
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.9448 | -1.15 – -0.569 | -1.65 | +42.9% | 0 | 0.0% | 5 |
| Next quarter | -0.8782 | -1.07 – -0.638 | -1.36 | +35.6% | 0 | 0.0% | 5 |
| Current year | -3.71 | -4.43 – -2.86 | -5.91 | +37.4% | 0 | 0.0% | 4 |
| Next year | -2.54 | -3.04 – -2.04 | -3.71 | +31.4% | 11.07M | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2026 | Barclays | Initiated | — | Overweight |
| Aug 20, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jul 27, 2026 | Wells Fargo | Initiated | — | Overweight |
| Jul 9, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 1, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Apr 13, 2026 | TD Cowen | Initiated | — | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 3, 2025 | Guggenheim | Maintained | Buy | Buy |
| Nov 20, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 14, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |